Posted by Michael Wonder on 11 Dec 2025
ICER releases draft evidence report on therapies for IgA nephropathy
10 December 2025 - Public comment period now open until 14 January 2026; Requests to make oral comment during public meeting also being accepted.
The ICER today released a draft evidence report assessing the comparative clinical effectiveness and value of sibeprenlimab (Voyxact, Otsuka), atacicept (Vera Therapeutics), and delayed-release budesonide (Nefecon, Tarpeyo, Calliditas Therapeutics) targeting abnormal complexes of immunoglobulin for IgA nephropathy.
